GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Pomalidomide - POMALYST capsules

Local official-label summaryBase record retrieved 2026-09-09See the evidence for this drug2 sources available - open source summaries, references and comparisons

POMALYST / Pomalidomide

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
POMALYST: indication, cycle days and HD timing remain linked

The dialysis dose differs between multiple myeloma and Kaposi sarcoma. The renal change does not remove the treatment-free portion of the 28-day cycle.

Before applying: Confirm indication, days on treatment and post-HD administration; do not turn the modified dose into uninterrupted daily treatment.

Also check: POMALYST: indication, cycle days and HD timing remain linked

Official source

POMALYST - official hemodialysis and indication check

Product / population
POMALYST - official hemodialysis and indication check; selected renal passages, not a complete prescribing monograph.
Renal measure
Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage.

Identity check: DailyMed labeler Celgene Corporation. Current archive version 26 published 2025-05-12. This archive date is separate from the prescribing-information revision and does not itself prove that renal instructions changed. Raw SPL XML was not independently downloaded or hashed.

Renal dosing, restrictions and evidence limits

The official label confirms distinct dialysis reductions: 3 mg daily for multiple myeloma and 4 mg daily for Kaposi sarcoma. Both retain days 1-21 of 28-day cycles. On hemodialysis days, give the dose after dialysis. This confirmation addresses selected renal instructions, not complete protocol validation; independent review of the full regimen remains pending.

Source revision: Prescribing information revised February 2025. | Retrieved: 2026-09-09. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

POMALYST - official hemodialysis and indication check

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

POMALYST - official hemodialysis and indication check; selected renal passages, not a complete prescribing monograph.

Renal method: Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage.
Retrieved: 2026-09-09

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - POMALYST

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Pomalidomide - POMALYST capsules; selected renal passages, not a complete prescribing monograph.

Renal method: Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage.
Retrieved: 2026-09-09

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

POMALYST: indication, cycle days and HD timing remain linked

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

dialysis scope

POMALYST: indication, cycle days and HD timing remain linked

The dialysis dose differs between multiple myeloma and Kaposi sarcoma. The renal change does not remove the treatment-free portion of the 28-day cycle.

How to use this: Confirm indication, days on treatment and post-HD administration; do not turn the modified dose into uninterrupted daily treatment.

GlobalRPh RX List - POMALYSTPOMALYST - official hemodialysis and indication check

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopePOMALYST - official hemodialysis and indication checkGlobalRPh RX List - POMALYST
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/pomalyst-drug/

Exact product and population

Pomalidomide - POMALYST capsules; selected renal passages, not a complete prescribing monograph.

RDM50-SCOPE-pomalidomide-pomalyst · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

POMALYST - official hemodialysis and indication check

Open original reference

Open / share this exact local source

DailyMed / Celgene Corporation · POMALYST - official hemodialysis and indication check; selected renal passages, not a complete prescribing monograph.

Renal method: Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage.
Source date: Prescribing information revised February 2025.
Retrieved: 2026-09-09

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The official label confirms distinct dialysis reductions: 3 mg daily for multiple myeloma and 4 mg daily for Kaposi sarcoma. Both retain days 1-21 of 28-day cycles. On hemodialysis days, give the dose after dialysis. This confirmation addresses selected renal instructions, not complete protocol validation; independent review of the full regimen remains pending.

RDM50-official-pomalidomide-pomalyst-bd6e83f3f3-C1 · Source locator: Sections 2.2-2.3, lines 409-414; section 2.7, lines 513-520.

Source-specific limits

Identity check: DailyMed labeler Celgene Corporation. Current archive version 26 published 2025-05-12. This archive date is separate from the prescribing-information revision and does not itself prove that renal instructions changed. Raw SPL XML was not independently downloaded or hashed.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66
Retrieved
2026-09-09
Exact label title
POMALYST- pomalidomide capsule
DailyMed Set ID
2b25ef01-5c9e-11e1-b86c-0800200c9a66
Labeler
Celgene Corporation
Label revision
Prescribing information revised February 2025.
Archive publication date
2025-05-12
SPL version
26
FDA application
NDA204026
Renal-function method
Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage.
Source date/version
Prescribing information revised February 2025.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
8612fb5804847f89ebb2a38ee4abb6df0ae9ab331a8152ce28e5f3c46932ff7b
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - POMALYST

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Pomalidomide - POMALYST capsules; selected renal passages, not a complete prescribing monograph.

Renal method: Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-09

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For severe renal impairment requiring hemodialysis, the reduced oral daily dose is 3 mg for multiple myeloma and 4 mg for Kaposi sarcoma. Retain the indication-specific cycle: dosing on days 1-21 of each 28-day cycle, not every day throughout the cycle. Give the dose after hemodialysis on dialysis days. The renal PK findings for nondialysis CrCl 15 to <60 mL/min do not justify transferring the dialysis reduction to every patient in those bands. These are renal starting modifications, not a substitute for hematologic, hepatic, interaction, thrombosis-prevention and pregnancy safeguards.

RDM50-rxlist-pomalidomide-pomalyst-5cf2355d72-C1 · Source locator: Dosage: MM/KS cycles, lines 57-62; hemodialysis, lines 143-148; renal PK, lines 730-733.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/pomalyst-drug/
Retrieved
2026-09-09
Renal-function method
Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
a4d34f4489ec9493471e8a426fb47254a77d0633c7041768746b48602791cccc

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/pomalyst-drug/
Source retrieval
2026-09-09. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
f2f4c9fcb4d182a116440efa28c0c261f001bc4100e3dab5d5d2b56b795dceba
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report